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ABSTRACT
Introduction: Sustained optimal adherence to antiretroviral therapy (ART) is required for long-term suppression of vi-
ral replication. However, adherence level in Jos, Nigeria has been reported to be below optimal adherence, thus this 
study investigates the predictors of adherence to antiretroviral therapy among Human Immunodeficiency Virus (HIV) 
patients there.  Methods: A validated and pretested questionnaire was used in this cross-sectional study to collect 
data on sociodemographic characteristics, duration of being on ART, alcohol consumption, presence of symptoms, 
drug type and disclosure status from 224 randomly selected adult HIV patients. Chi-square and binary logistics re-
gression were used for data analysis. Level of significance was set at 0.05. Results: Only 14.3% of the respondents 
had optimal adherence. Adherence to ART is significantly associated with gender (p = 0.043), duration of ART use 
(p = 0.041), alcohol (p = 0.029), drug type (p = 0.001), and disclosure status (p = 0.004). Binary logistics regression 
reveals that females are 2.4 times more likely to have optimal adherence than males, patients on ART for over 10 
years are 2.5 times more likely to have optimal adherence than those less than 10 years, and patients with disclosed 
HIV status are 3.3 times more likely to have optimal adherence than those who had not. Conclusion: Generally, the 
patients had suboptimal adherence. Being female, having longer duration on ART and disclosure status are predictors 
for optimal adherence. Intervention with emphasis on males and new patients on ART is recommended to educate 
on optimal adherence and motivate patients to disclose their status.
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INTRODUCTION
The pandemic of Human Immunodeficiency Virus (HIV) 
and Acquired Immune Deficiency Syndrome (AIDS) has 
led to serious health and socioeconomic challenges for 
more than two decades. Apart from being the second 
country with the largest HIV epidemic in the world, 
Nigeria records one of the highest rates of new infections 
in sub-Saharan Africa (1). The advent of antiretroviral 
therapy (ART) propelled a significant downturn in HIV-
related morbidity and mortality hence, HIV infection is 
currently managed as a chronic disease (2). The goal 
of ART is long-term suppression of viral replication and 
this is one of the principal considerations in lifelong 
HIV prognosis (3). While the importance of ART is 
well established and cannot be overemphasized, poor 
adherence to the regimens is persistent (4). Adherence to 
medication is defined by the World Health Organization 
(WHO) as “the degree to which the person’s behaviour 
corresponds with the agreed recommendations from 
a health care provider.” Non adherence to ART 
amplifies the risk of viral mutations, resulting in cross-
resistance to several antiretrovirals or spread of multi 
resistant virus strains,  consequently increasing the 
probability of treatment failure in subsequent naïve 
patients (5). Evidence of primary studies revealed 
how occasionally, good adherence fail to prevent 
multiplication of antiretroviral resistance mutation, 
and as such suboptimal adherence is still considered a 
crucial concern in HIV drug resistance (6). Adherence is 
essential for a guaranteed effective ART and virological 
suppression and is considered as the second strongest 
predictor (after CD4 count) of rapid progression to AIDS 
(7).
Suboptimal adherence to ART (<95% adherence level) 
can lead to inadequate suppression of HIV virus and 
also proliferation of drug-resistant strains of HIV-1 (8), 
leading to treatment failure, progression of disease, and 
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risk of disseminating resistant virus strains which chiefly 
impedes the goal ART. Thus, it is crucial to promote 
optimal ART adherence and appropriate treatment 
for maintaining viral suppression which is the goal of 
successful HIV treatment; as suboptimal adherence in 
itself is central in causing treatment failure. The World 
Health Organisation recommends that a minimum of 
95% ART adherence which is optimal adherence level, 
is to be maintained as a prerequisite for successful 
treatment (9). 
Predictors of ART adherence as reported by past 
studies consist of patient factors which include 
sociodemographic factors like age, education, income, 
and social status; type of treatment such as type, number 
of pills, complexity; characteristics of the disease such 
as HIV clinical stage, associated signs and symptoms, 
opportunistic infections associated with the disease; 
healthcare provider relationship factors such as patient 
satisfaction, therapeutic relationship, communication; 
and health facility factors such as accessibility, adherence 
programme, environment (10–12). Meanwhile 
common predictors of non-adherence include marital 
status, alcohol consumption, non-disclosure to family 
members, cigarette smoking, stigma, forgetfulness, side 
effects and being away from home (13).
Exploring the predictors of adherence is crucial for 
designing interventions targeted at improving optimal 
adherence in the community. In addition to serving as a 
guide for planning the management of HIV patients, this 
knowledge could enable health care providers and policy 
makers to identify barriers against adherence which 
interfere with treatment success.  This could be achieved 
by designing intervention programs that will address the 
factors associated with suboptimal adherence, in order 
to improve adherence to optimal level thus thwarting 
viral replication and disease progression.
MATERIALS AND METHODS
Study Design and Samples
This was a cross-sectional study involving 224 HIV 
patients who had viral load greater than 1000 copies/
mL and receiving ART at AIDS Prevention Initiative in 
Nigeria (APIN) clinic of JUTH, Plateau State, Nigeria. 
This treatment centre is renowned for its provision of 
clinical services on HIV/AIDS ranging from prevention, 
care and treatment comprising of free drugs, diagnostics, 
and clinical services.  Sample size calculated 224 
was using formula for comparing two means and 
based on CD4 count variable by a pilot study of food 
supplementation to improve adherence to antiretroviral 
therapy among food-insecure adults in Lusaka, Zambia 
(14). Then simple random sampling was used to select 
from a list of patients who had viral load above 1000 
copies/mL. Inclusion criteria into the study included 
all HIV positive patients on ART aged 18 years and 
above, with viral load greater than 1000 copies/mL on 
ART for at least 6 months, irrespective of CD4 count 
and yet to undergo enhanced adherence counselling. 
Patients excluded from the study were non-ambulatory 
or hospitalised patients, pregnant women, patients 
restarting their ART due to prior default, patients with 
psychological disorders, patients with comorbidities, 
and patients on second-line regimens.
Ethical Clearance
The ethical approval of UPM Ethics committee for 
human research (JKEUPM) with ref. no UPM/TNCPI/
RMC/JKEUPM/1.4.18.2 and the Jos University Teaching 
Hospital (JUTH) Review and Ethics Committee with 
ref. no. JUTH/DCS/ADM/127/XXVII/631 were sought 
for review and approval. The trial was also registered 
with the Pan African Clinical Trial Registry (PACTR) with 
ref. no PACTR201811482580522. Written informed 
consent was also obtained from each respondent before 
data collection.
Data collection and analysis
Data was collected using The Adult AIDS Clinical Trial 
Group (AACTG) questionnaire. AACTG was adapted 
from previous clinical research (15) and it was pretested 
and revalidated for data collection in this study, with 
Cronbach α > 0.7. Questionnaires were interviewer 
administered and was obtained from all 224 respondents. 
The instrument
The questionnaire contained sub-sections ranging from 
patient’s demographic profile, history of alcohol use, 
review of symptoms, and questions on the regimens 
taken.
Patient’s demographic profile includes age, gender, 
residence, occupation, marital status, State of origin, 
educational level, disclosure status, and duration of 
known HIV status.
History of alcohol use (past and present) with frequency 
of alcohol intake in the last 30 days on a 7-point Likert 
scale was obtained ranging from “Daily”, “Nearly Every 
day”, “3 or 4 Times a week”, “Once or Twice a week”, 
“2 or 3 Times a month”, “Once A Month” and “Never”. 
In the chi-square bivariate analysis, the options “Daily” 
and “Nearly every day” were categorised as “heavy” 
alcohol users,  “3 or 4 Times a week” and “Once or 
Twice a week” were categorised as “moderate” alcohol 
users, “2 or 3 Times a month” and “Once A Month” 
were categorised as “light” alcohol users, while “never” 
was classified as “none”. For the binary logistics 
regression model, history of alcohol consumption was 
later categorised to “low” or “high” alcohol user.
Symptoms the patient experienced in the past four weeks 
were graded on a 5-point scale ranging from “none” to 
“I have this symptom” and…“it doesn’t bother  me”, “it 
bothers me a little”, “it bothers me a lot” and “it bothers 
me terribly” was obtained. It was later categorised to 
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“yes” or “no”. 
Data on drug combination, dosage, number of pills each 
dose, dose per day, and duration on ART was also taken. 
A ‘4-day recall of pills missed’ with options “Yesterday”, 
“two days ago”, “three days ago”, and “4 days ago” was 
obtained.
Self-reported adherence was measured based on a 4-day 
recall of ART medication taken by the respondent in the 
last four days. A 4-day recall was used because shorter 
time frame has been reported to have better potential for 
more accurate recall. It was calculated by the adapted 
formula from a previous prospective cohort study on 
HIV patients (15). Formula is as shown below,  
Adherence (%) = Total Prescribed pills(30 days) – Total pills missed(4days)  *100
                                 Total pills Prescribed(30 days) 
Therefore the adherence of a patient who missed; 
          (a) 1 day medication is 97%,
          (b) 2 days medication is 93%
          (c) 3 days medication is 90%
          (d) 4 days medication is 87%
 
Hence, an adherence ≥95% by a respondent is termed 
“optimal adherence” while adherence <95% is termed 
“suboptimal adherence”.
Content and face validity testing were carried out on the 
questionnaire and reliability testing on 30 respondents 
showed Cronbach’s alpha ranging from 0.505 to 0.938.
Data Analysis
Data was analysed using Statistical Package for Social 
Sciences (IBM SPSS) version 25; descriptive analysis 
was achieved using frequency and percentages, mean 
and standard deviation, to determine the respondent’s 
characteristics. Bivariate analysis was done using chi-
square, in order to determine statistically significant 
associations between the independent variables and 
the outcome variable.  Multivariate analysis was done 
using binary logistics regression, to identify predictors 
of adherence. Level of significance in the preliminary 
model of simple logistics regression was set at p<0.25. 
Confounders were controlled while adjusting for 
covariates in the exp. (β) (adjusted odds ratio) from simple 
logistics regression to multiple logistics regression. 
Thereafter, all the significant variables were analysed 
using the ‘ENTER’ method and the level of significance 
was set at p<0.05.
RESULTS
Distribution of respondents
The results revealed that a majority of the respondents 
had suboptimal adherence to ART (85.7%) while only 
14.3% had optimal adherence (Table I). Furthermore, 
the mean ART adherence of the respondents is 90.34% 
(3.315%) implying that the overall ART adherence of the 
respondents was suboptimal. 
Demographic Distribution of the respondents 
The findings of this study showed that a majority of the 
respondents were between the ages of 41 to 50 years 
(37.9%), more than half were females (59.8%), were 
urban dwellers (63.8%), and mostly married (67.7%). 
Furthermore, the results showed that the majority of 
respondents (48.2%) had been on ART for a longer 
duration (11-20 years). Also, majority were non-
consumers of alcohol (80.8%) while more than half 
of the respondents (67%) had presence of symptoms. 
Quite an appreciable proportion (85.7%) were on the 
AZT/3TC/NVP regimen, and slightly more than half of 
the respondents (54.5%) had  undisclosed HIV status 
(Table II). 
Factors associated with ART adherence
The results in table III show that gender was significantly 
associated with ART adherence (p=0.043); with 17.9% 
of females having optimal adherence while only 8.9% 
of males were optimally adherent, implying that females 
were more optimally adherent than males. The duration 
on ART was also found to be associated with ART 
adherence (p = 0.012); with 20.4% of those on ART 
for over 10 years having optimal adherence compared 
to only 8.6% of those on ART for less than 10 years. 
Furthermore, alcohol consumption was found to be 
significantly associated with ART adherence (p = 0.049); 
with 15.8% of low consumers having optimal adherence 
while no high consumer (0%) was optimally adherent. 
Similarly, type of regimen was found to be associated 
with ART adherence (p = 0.001); with 26.2% of those on 
AZT/3TC/NVP regimen being optimally adherent while 
none (0%) of those on TDF/3TC/EFV was found to have 
optimal adherence. Disclosure status was significantly 
associated with ART adherence (p = 0.004); with 21.9% 
of those with disclosed HIV status having optimal 
adherence while only 7.6% of those with undisclosed 
HIV status were optimally adherent.
Predictors of ART adherence
Binary logistic regression was done to obtain factors 
predicting ART adherence in HIV patients. Six variables 
were included in the preliminary model of simple 
logistics regression, after which four variables were found 
to be significant at p<0.25, these variables were; gender, 
presence of symptoms, duration on ART, and HIV 
disclosure status. Thereafter, all the four variables were 
analysed using the ‘ENTER’ method and three variables 
were found to be significant at p<0.05. Multicollinearity 
Table I: Adherence score and level of ART adherence (N=224)
Variable n % Mean SD
Adherence score 90.34 3.315
Suboptimal adherence 192 85.7
Optimal adherence 32 14.3
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was not detected; neither was significant interactions 
between variables. The model fits the sample as p = 
0.382 for Hosmer-Lomeshow. The Negelkerke’s R 
squared showed that only about 16.7% of the variation 
in optimal adherence to ART is explained by this 
logistic model. As such, there was likelihood that other 
Table II: Characteristics of the respondents (N=224)
Variables n %
Age 
20-30 15 6.7
31-40 74 33
41-50 85 37.9
51 above 50 22.3
Gender 
Male 90 40.2
Female 134 59.8
Residence 
Urban 143 63.8
Rural 81 36.2
Occupation 
Student 8 3.6
Civil service 94 42
Business 96 42.9
Unemployment 26 11.6
Marital status
Single 17 7.6
Married 152 67.9
Divorced 17 7.6
Widowed 38 17
Education 
None 15 6.7
Primary 52 23.2
Secondary 63 28.1
Tertiary 94 42
Duration on ART
<5 years 41 18.3
5-10 years 75 33.5
11-20 years 108 48.2
Alcohol consumption
None 181 80.8
Light 22 9.8
Moderate 11 4.9
Heavy 10 4.5
Presence of symptoms
Yes 150 67
No 74 33
Drug type 
AZT/3TC/NVP 192 85.7
TDF/3TC/EFV 32 14.3
HIV Disclosure status
Yes 102 45.5
No 122 54.5
Table III: Factors associated with level ART adherence (N=224)
Variables Level of ART adherence χ2 p 
value
Optimal Suboptimal
n % n %
Age 1.276 0.735
20-30 1 6.7 14 93.3
31-40 11 14.9 63 85.1
41-50 14 16.5 71 83.5
51 above 6 12.0 44 88.0
Gender 3.579 0.043*
Male 8 8.9 82 91.1
Female 24 17.9 110 82.1
Residence 0.570 0.352
Urban 19 13.3 124 86.7
Rural 13 16 68 84
Occupation 0.933 0.817
Student 2 25 6 75
Civil service 13 13.8 81 86.2
Business 14 14.6 82 85.4
Unemployment 3 11.5 23 88.5
Marital status 0.934 0.817
Single 2 11.8 15 88.2
Married 20 13.2 132 86.8
Divorced 3 17.6 14 82.4
Widowed 7 18.4 31 81.6
Education 3.650 0.302
None 1 6.7 14 93.3
Primary 4 7.7 18 92.3
Secondary 11 17.5 52 82.5
Tertiary 16 17 78 83
Duration on ART 6.306 0.012*
<10 years 10 8.6 106 91.4
>10 years 22 20.4 86 79.6
Alcohol consump-
tion
3.862 0.049*
Low 32 15.8 171 84.2
High  0 0 21 100
Presence of symp-
toms
0.164 0.222
Yes 18 12 132 88.0
No 14 18.9 60 81.1
Drug type 31.213 0.001*
AZT/3TC/NVP 32 26.2 90 73.8
TDF/3TC/EFV 0 0 102 100
HIV Disclosure 
status
9.370 0.004*
Yes 23 21.9 82 78.1
No 9 7.6 110 92.4
Note: (*) – significant p < 0.05 
predictors of ART adherence other than those included 
in this study exist. From the results on table IV, it was 
deduced that females were 2.413 times more likely to 
have optimal adherence than males, patients taking ART 
for more than 10 years were 2.537 times more likely to 
be optimally adherent than those on ART for less than 
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10 years, and patients that had disclosed their HIV status 
were 3.391 times more likely to be optimally adherent 
than those with undisclosed HIV status.
DISCUSSION
Adherence to antiretroviral therapy which entails 
judiciously taking the recommended prescription, was 
categorised in this study as either optimal (95% and 
above) or suboptimal (below 95%). According to the 
findings of this study, adherence level of the respondents 
was found to be suboptimal. Although treatment-
experienced, these respondents had viral load above 
1000 copies/mL implying virologic failure. As suggested 
by previous literature, suboptimal adherence is a major 
factor contributing to virologic failure and treatment 
discontinuations (17). Suboptimal adherence was 
reported to be robustly associated with virologic failure 
(18) and can take the form of treatment defaulting and 
treatment interruption, incomplete dosing and inaccurate 
observance of medication time, frequency and dosage . A 
defaulter was defined as an HIV positive patient on ART, 
who had missed one monthly clinic appointment while 
treatment interruption referred to defaulted patients who 
have returned to care. Missing appointment schedules 
has been reported to be associated with missed doses 
(19), while missing pharmacy refills, missed doses and 
missed clinic appointment are causes of nonadherence 
(20). This finding is akin to the findings of some studies 
(21,22) which reported poor adherence. Contrarily, the 
findings of a study (22) reported 73.7% of respondents 
having optimal ART adherence, other studies have 
also reported a higher optimal adherence (8,24,25). 
Suboptimal adherence is one of the most common 
reasons for treatment failure which poses a risk for 
developing drug resistance through suboptimal viral 
suppression, with resulting poor health outcomes and 
increasing healthcare costs (26).
Gender was found to have a significant association with 
ART adherence in this study, and more females were 
observed to have optimal adherence (17.9%) than males 
(8.9%). This is consistent with findings of some studies 
(27,28), while other studies have reported contrary 
findings (15,29). The finding of the present study could 
be attributed to poor health-seeking behaviour in 
males compared to females (30,31). It is expected that 
people with good health-seeking behaviour will exhibit 
good health behaviour such as adherence to regimens 
and scheduled clinic appointments. This is because, 
adherence information is sought in the course of health-
seeking activities and as knowledge is increased, so to 
is adherence to regimens. Furthermore, it is reported 
that health seeking behaviour may lead to an increase 
in medication self-efficacy thereby leading to adherence 
(32). In viewing gender from a socio-cultural perspective, 
it has been asserted that both women and men seek care 
from informal and formal institutions however, their 
motives differ which results to dissimilar health-seeking 
outcomes. While women’s role in conserving socio-
cultural norms steers them to centre on long discussions 
with socio-cultural traits which evades social and 
economic consequences, men on the other hand seek 
fast and absolute recovery in order to prevent financial 
pressure (33). Gender in this study was found to be a 
predictor of optimal adherence in this study, and female 
patients were two times more likely to have optimal 
adherence than males. 
Furthermore, respondents who had been on ART for 
a period of more than 10 years were found to have 
more optimal adherence compared to those who had 
been on it for a period of less than 10years (8.6%). 
While an explanation to this could be that patients get 
accustomed to the medication after a long period of 
time and integrate it into their daily routine resulting 
in lifestyle changes; treatment fatigue on the other 
hand is inextricably linked to ART adherence and is 
identified as a consequence of long-term regimen (34). 
However, treatment-experienced patients who have 
Table IV:  Predictors of ART adherence among HIV positive patients (N=224)
Variable B S.E Wald df p value Exp (B) 95% CI
Lower
95% CI
Upper
Gender 
Male 1.000
Female 0.881 0.467 3.564 1 0.049* 2.413 1.007 6.020
Duration on ART
<10 years 1.000
>10 years 0.931 0.472 4.752 1 0.029* 2.537 1.099 5.859
Symptoms 
No 1.000
Yes -0.395 0.433 0.835 1 0.361 0.673 0.288 1.573
Disclosure status
No 1.000
Yes 1.221 0.444 7.581 1 0.006* 3.391 1.422 8.090
Constant -7.261 1.696 18.329 1 0.001 0.001
 Note: (*) – significant p < 0.05 
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longer duration on ART are said to have understood 
the concept of long-term therapies hence present with 
less suboptimal adherence problems. Patients who have 
been on ART for a very long time must have had quite 
appreciable sessions of adherence counselling which 
increase their knowledge and understanding of ART thus 
improving adherence. However some studies reported 
no significant association between duration on ART and 
adherence to ART (35). Duration on ART was found to 
be a predictor of optimal adherence in this study, and 
patients who were on ART for more than 10 years were 
two times more likely to have optimal adherence than 
those who were on ART for less than 10 years. 
Alcohol consumption was found to be significantly 
associated with ART adherence in this study. While 
15.8% respondents who were low consumers of 
alcohol were found to have optimal adherence, no 
high consumer of alcohol recorded optimal adherence. 
This finding agrees with the findings of other studies 
(36,37). Alcohol use has been reported to be one of the 
strongest predictors of non-adherence to ART (38), this 
is because many HIV patients often use alcohol to cope 
with perceived stress experienced by most HIV patients 
(39). Besides interactive toxicity beliefs linked to alcohol 
consumption while on ART, treatment interruption has 
been strongly associated with alcohol consumption thus 
resulting in poor adherence. Heavy drinkers have been 
reported to have even higher rates of nonadherence. 
Identifying the cause of the nonadherence among HIV 
positive alcohol users has been suggested to increase 
their adherence (40). Additionally, interventions to 
improve ART adherence and routine counselling sessions 
in clinics should include alcohol counselling content in 
their programs according to the level of understanding 
of each patient. 
The type of ART regimen the respondents were taking 
was found to be significantly associated with ART 
adherence, a few of those on AZT/3TC/NVP (26.2%) 
had optimal adherence while those on TDF/3TC/
EFV recorded no optimal adherence. While it is a bit 
unusual for multiple-tablet regimens such as AZT/3TC/
NVP to have higher adherence rates than single-tablet 
regimens such as TDF/3TC/EFV due to pill burden, it 
is noteworthy to state that pill burden which leads to 
treatment fatigue may not be a significant reason for 
non-adherence in treatment-experienced patients. This 
could be the explanation for the finding of the present 
study, because the respondents of this study were 
all treatment-experienced. Furthermore, AZT/3TC/
NVP combination was introduced to the clinic before 
TDF/3TC/EFV combination, which explains why pill 
burden and treatment fatigue may not affect both groups 
of patients. It is expected that respondents on AZT/3TC/
NVP would be more experienced than those on 
TDF/3TC/EFV, and would have understood adherence 
to life-long regimens better thereby incorporating it into 
their routine. Generally, compared to multiple-tablet 
regimens, single-tablet regimens have demonstrated 
higher adherence rates, and improved viral suppression 
due to their lower pill burdens (41). Nonetheless, most 
of these findings are reports from studies involving 
treatment-naïve patients.
Disclosure of HIV status by the respondents was found 
to be significantly associated with ART adherence, 
respondents who disclosed their HIV status (21.9%) 
were more optimally adherent than those who had not 
disclosed (7.6%). The finding is similar to the findings 
of other studies (36,42). Disclosure of HIV status by 
the patient enables patients to seek social support and 
lessens the burden of self-discrimination and pressure of 
consistent medication intake. Non-disclosure is reported 
to be associated with low social support (43), poor 
adherence rates and depression (42). Some studies on 
the contrary found no significant association between 
disclosure status and ART adherence (22). Disclosure 
status was found to be a predictor of optimal adherence 
in this study, patients who had disclosed their HIV status 
were three times more likely to be optimally adherent 
than patients who had not.
CONCLUSION
The respondents in this study had suboptimal 
adherence. Factors such as gender, duration on ART, 
and disclosure status were found to be the predictors 
of optimal adherence although, alcohol consumption 
and type of ART were also associated with ART 
adherence. Interventions to improve optimal adherence 
is recommended with more emphasis on males, patients 
starting ART and patients with undisclosed HIV status. 
Interventions to address the needs of male patients 
related to ART adherence is requisite to improve optimal 
adherence. 
In addition, theory-based interventions such as the 
information-motivation-behavioural skills (IMB) model 
intervention should be designed and implemented 
for improving ART adherence. The behavioural skills 
content of the IMB-based intervention should be targeted 
at treatment-naïve patients in order to prevent any 
future occurrence of treatment failure. Behavioural skills 
related to ART adherence will include incorporating 
medication schedule into activities of daily living, 
utilizing reminder cues such as pill boxes, medication 
diaries and associating meal times with medication 
timing.  
Furthermore, the motivation content of the IMB-
based intervention will address the attitude and 
beliefs of patients relating to HIV as well as dispelling 
negative social norms regarding HIV. This will include 
counselling patients to allay any fear of discrimination 
and stigmatization. In addition, this will encourage 
patients to disclose their status and improve patient-
social support relationship and participation, thereby 
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improving optimal adherence. Lastly, other determinants 
of ART adherence which were not included in this study 
should be further researched.
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